BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, Friedlander PA, Daud A, Kluger HM, Reddy SA, Boulmay BC, Riker A, Burgess MA, Hanks BA, Olencki T, Kendra K, Church C, Akaike T, Ramchurren N, Shinohara MM, Salim B, Taube JM, Jensen E, Kalabis M, Fling SP, Homet Moreno B, Sharon E, Cheever MA, Topalian SL. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer 2021;9:e002478. [PMID: 33879601 DOI: 10.1136/jitc-2021-002478] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 19.0] [Reference Citation Analysis]
Number Citing Articles
1 Hooiveld-noeken JS, Eggen AC, Rácz E, de Vries EG, Reyners AK, Jalving M. Towards less mutilating treatments in patients with advanced non-melanoma skin cancers by earlier use of immune checkpoint inhibitors. Critical Reviews in Oncology/Hematology 2022;180:103855. [DOI: 10.1016/j.critrevonc.2022.103855] [Reference Citation Analysis]
2 Akaike T, Cahill K, Akaike G, Huynh ET, Hippe DS, Shinohara MM, Liao J, Apisarnthanarax S, Parvathaneni U, Hall E, Bhatia S, Cheng RK, Nghiem P, Tseng YD. Management and Prognosis of Cardiac Metastatic Merkel Cell Carcinoma: A Case–Control Study and Literature Review. Cancers 2022;14:5914. [DOI: 10.3390/cancers14235914] [Reference Citation Analysis]
3 Dimitraki MG, Sourvinos G. Merkel Cell Polyomavirus (MCPyV) and Cancers: Emergency Bell or False Alarm? Cancers 2022;14:5548. [DOI: 10.3390/cancers14225548] [Reference Citation Analysis]
4 Esser E, Grünewald I, Mihailovic N. Das periokuläre Merkel-Zell-Karzinom – eine Übersicht klinischer Aspekte und aktueller Therapieoptionen. Klin Monbl Augenheilkd 2022. [DOI: 10.1055/a-1925-7703] [Reference Citation Analysis]
5 Lewis DJ, Sobanko JF, Etzkorn JR, Shin TM, Giordano CN, Mcmurray SL, Walker JL, Zhang J, Miller CJ, Higgins HW. Merkel Cell Carcinoma. Dermatologic Clinics 2022. [DOI: 10.1016/j.det.2022.07.015] [Reference Citation Analysis]
6 Aboul-fettouh N, Kubicki SL, Chen L, Silapunt S, Migden MR. Targeted Therapy and Immunotherapy in Nonmelanoma Skin Cancer. Dermatologic Clinics 2022. [DOI: 10.1016/j.det.2022.07.009] [Reference Citation Analysis]
7 Saiag P, Blom A. Combined nivolumab and ipilimumab in non-resectable Merkel cell carcinoma. The Lancet 2022;400:976-7. [DOI: 10.1016/s0140-6736(22)01749-4] [Reference Citation Analysis]
8 Church C, Pulliam T, Longino N, Park SY, Smythe KS, Makarov V, Riaz N, Jing L, Amezquita R, Campbell JS, Gottardo R, Pierce RH, Choi J, Chan TA, Koelle DM, Nghiem P. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma. J Immunother Cancer 2022;10:e005328. [DOI: 10.1136/jitc-2022-005328] [Reference Citation Analysis]
9 Kim S, Wuthrick E, Blakaj D, Eroglu Z, Verschraegen C, Thapa R, Mills M, Dibs K, Liveringhouse C, Russell J, Caudell JJ, Tarhini A, Markowitz J, Kendra K, Wu R, Chen D, Berglund A, Michael L, Aoki M, Wang M, Hamaidi I, Cheng P, de la Iglesia J, Slebos RJ, Chung CH, Knepper TC, Moran-segura CM, Nguyen JV, Perez BA, Rose T, Harrison L, Messina JL, Sondak VK, Tsai KY, Khushalani NI, Brohl AS. Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial. The Lancet 2022;400:1008-19. [DOI: 10.1016/s0140-6736(22)01659-2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wang AJ, Mccann B, Soon W, Ieso PB, Bressel M, Hui A, Chua M, Kok D. Merkel cell carcinoma: A Forty-year experience at the Peter MacCallum Cancer Centre.. [DOI: 10.21203/rs.3.rs-1858826/v1] [Reference Citation Analysis]
11 Silk AW, Barker CA, Bhatia S, Bollin KB, Chandra S, Eroglu Z, Gastman BR, Kendra KL, Kluger H, Lipson EJ, Madden K, Miller DM, Nghiem P, Pavlick AC, Puzanov I, Rabinowits G, Ruiz ES, Sondak VK, Tavss EA, Tetzlaff MT, Brownell I. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer. J Immunother Cancer 2022;10:e004434. [PMID: 35902131 DOI: 10.1136/jitc-2021-004434] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Zelin E, Maronese CA, Dri A, Toffoli L, Di Meo N, Nazzaro G, Zalaudek I. Identifying Candidates for Immunotherapy among Patients with Non-Melanoma Skin Cancer: A Review of the Potential Predictors of Response. J Clin Med 2022;11:3364. [PMID: 35743435 DOI: 10.3390/jcm11123364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Spada F, Bossi P, Caracò C, Sileni VC, Dei Tos AP, Fazio N, Grignani G, Maio M, Quaglino P, Queirolo P, Ascierto PA; DELPHI Panel Members. Nationwide multidisciplinary consensus on the clinical management of Merkel cell carcinoma: a Delphi panel. J Immunother Cancer 2022;10:e004742. [PMID: 35701070 DOI: 10.1136/jitc-2022-004742] [Reference Citation Analysis]
14 Ursu RG, Damian C, Porumb-Andrese E, Ghetu N, Cobzaru RG, Lunca C, Ripa C, Costin D, Jelihovschi I, Petrariu FD, Iancu LS. Merkel Cell Polyoma Virus and Cutaneous Human Papillomavirus Types in Skin Cancers: Optimal Detection Assays, Pathogenic Mechanisms, and Therapeutic Vaccination. Pathogens 2022;11:479. [PMID: 35456154 DOI: 10.3390/pathogens11040479] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mazziotta C, Lanzillotti C, Gafà R, Touzé A, Durand MA, Martini F, Rotondo JC. The Role of Histone Post-Translational Modifications in Merkel Cell Carcinoma. Front Oncol 2022;12:832047. [PMID: 35350569 DOI: 10.3389/fonc.2022.832047] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Park SJ, Kannan A, Harris JP, Lacy C, Daniels GA, Lee SP, Lambrecht N, Hook N, Olshan P, Billings PR, Aleshin A, Gao L. Circulating tumor DNA as a predictive biomarker in Merkel cell carcinoma. J Am Acad Dermatol 2022:S0190-9622(22)00503-5. [PMID: 35318107 DOI: 10.1016/j.jaad.2022.03.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Gambichler T, Said S, Abu Rached N, Scheel CH, Susok L, Stranzenbach R, Becker JC. Pan-immune-inflammation value independently predicts disease recurrence in patients with Merkel cell carcinoma. J Cancer Res Clin Oncol. [DOI: 10.1007/s00432-022-03929-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Liu W, Alameh M, Yang JF, Xu JR, Lin PJ, Tam YK, Weissman D, You J. Lipid nanoparticles delivering constitutively active STING mRNA as a novel anti-cancer therapeutic approach.. [DOI: 10.1101/2022.01.08.475499] [Reference Citation Analysis]
19 永瀬 浩. メルケル細胞ポリオーマウイルス. Skin Cancer 2022;37:79-83. [DOI: 10.5227/skincancer.37.79] [Reference Citation Analysis]
20 Akaike T, Nghiem P. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer. J Dermatol Sci 2021:S0923-1811(21)00252-8. [PMID: 34836718 DOI: 10.1016/j.jdermsci.2021.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Tanda ET, d'Amato AL, Rossi G, Croce E, Boutros A, Cecchi F, Spagnolo F, Queirolo P. Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale? Front Oncol 2021;11:739006. [PMID: 34631574 DOI: 10.3389/fonc.2021.739006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Goff PH, Bhakuni R, Pulliam T, Lee JH, Hall ET, Nghiem P. Intersection of Two Checkpoints: Could Inhibiting the DNA Damage Response Checkpoint Rescue Immune Checkpoint-Refractory Cancer? Cancers (Basel) 2021;13:3415. [PMID: 34298632 DOI: 10.3390/cancers13143415] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]